Autolus Therapeutics plc ADR (NASDAQ:AUTL)’s traded shares stood at 0.42 million during the latest session, with the company’s beta value hitting 2.07. At the last check today, the stock’s price was $1.71, to imply a decrease of -2.57% or -$0.04 in intraday trading. The AUTL share’s 52-week high remains $6.62, putting it -287.13% down since that peak but still an impressive -2.34% since price per share fell to its 52-week low of $1.75.
Analysts have given a consensus recommendation of Buy for Autolus Therapeutics plc ADR (AUTL), translating to a mean rating of 1.00. Of 3 analyst(s) looking at the stock, 0 analyst(s) give AUTL a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.24.
Autolus Therapeutics plc ADR (NASDAQ:AUTL) trade information
After registering a -2.57% downside in the latest session, Autolus Therapeutics plc ADR (AUTL) has traded red over the past five days. The 5-day price performance for the stock is -12.56%, and -20.33% over 30 days. With these gigs, the year-to-date price performance is -27.45%.
The extremes give us $7.6 and $7.6 for target low and target high price respectively. As such, AUTL has been trading -344.44% off suggested target high and -344.44% from its likely low.
Autolus Therapeutics plc ADR (AUTL) estimates and forecasts
The rating firms project that company’s revenue will grow 920.38% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is 2.98M. Meanwhile, for the current quarter, a total of 2 analyst(s) estimate revenue growth to 500k.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 3.32% for the past 5-year period. While 2025 is set for a 24.89% return in earnings, projections for the next 5 years are at 17.01% annually.
AUTL Dividends
Autolus Therapeutics plc ADR has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Autolus Therapeutics plc ADR (NASDAQ:AUTL)’s Major holders
The next major institution holding the largest number of shares is BLACKSTONE INC. with 20.49 million shares, or about 7.7006% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $71.29 million.
We also have Vanguard Specialized-Health Care Fund and Fidelity Small Cap Growth Fund as the top two Mutual Funds with the largest holdings of the Autolus Therapeutics plc ADR (AUTL) shares. Going by data provided on Oct 31, 2024, Vanguard Specialized-Health Care Fund holds roughly 19.36 shares. This is just over 7.27% of the total shares, with a market valuation of $32.91 million. Data from the same date shows that the other fund manager holds a little less at 2.57, or 0.97% of the shares, all valued at about 4.37 million.
